Novartis AG (NOVN):企業の財務・戦略的SWOT分析

◆英語タイトル:Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH24864FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年3月
◆ページ数:95
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Novartis AG (NOVN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Novartis AG Key Recent Developments

Mar 05,2021: Novartis announces change to the Executive Committee
Feb 17,2021: Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease
Feb 12,2021: Novartis: Expanding CAR-T manufacturing in Australia
Feb 11,2021: Acknowledged scientific leader and Novartis veteran joins Sai Life Sciences
Jan 26,2021: Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Novartis AG – Key Facts
Novartis AG – Key Employees
Novartis AG – Key Employee Biographies
Novartis AG – Major Products and Services
Novartis AG – History
Novartis AG – Company Statement
Novartis AG – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Novartis AG – Business Description
Business Segment: Innovative Medicines
Overview
Performance
Key Stats
Business Segment: Sandoz
Overview
Performance
Key Stats
Geographical Segment: Asia/Africa/Australasia
Performance
Performance
Geographical Segment: Canada and Latin America
Performance
Geographical Segment: Europe
Performance
Geographical Segment: The US
Performance
R&D Overview
Novartis AG – Corporate Strategy
Novartis AG – SWOT Analysis
SWOT Analysis – Overview
Novartis AG – Strengths
Novartis AG – Weaknesses
Novartis AG – Opportunities
Novartis AG – Threats
Novartis AG – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences, Power Financial Deals and Alliances
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Novartis AG, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 05, 2021: Novartis announces change to the Executive Committee
Feb 17, 2021: Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease
Feb 12, 2021: Novartis: Expanding CAR-T manufacturing in Australia
Feb 11, 2021: Acknowledged scientific leader and Novartis veteran joins Sai Life Sciences
Jan 26, 2021: Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020
Jan 26, 2021: Credence MedSystems receives a strategic investment from one of the world’s leading pharmaceutical companies
Jan 26, 2021: Novartis ranks second in 2021 Access to Medicine Index
Jan 19, 2021: Novartis and GSK announce collaboration to support scientific research into genetic diversity in Africa
Dec 08, 2020: RetinAI announces collaboration with Novartis to provide artificial intelligence solutions in ophthalmology
Nov 24, 2020: Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Novartis AG, Key Facts
Novartis AG, Key Employees
Novartis AG, Key Employee Biographies
Novartis AG, Major Products and Services
Novartis AG, History
Novartis AG, Subsidiaries
Novartis AG, Joint Venture
Novartis AG, Key Competitors
Novartis AG, Ratios based on current share price
Novartis AG, Annual Ratios
Novartis AG, Annual Ratios (Cont...1)
Novartis AG, Annual Ratios (Cont...2)
Novartis AG, Interim Ratios
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Novartis AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Novartis AG (NOVN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SK Chemicals Co Ltd (006120):製薬・医療:M&Aディール及び事業提携情報
    Summary SK Chemicals Co Ltd (SK Chemicals) is a chemical company that provides life sciences products and solutions. The company manufactures polyester and acetate yarns for textile, and industrial uses. Its copolyesters comprise ecozen, skygreen and skypets. SK Chemicals provides high-performance r …
  • Allinky Biopharma SL:製薬・医療:M&Aディール及び事業提携情報
    Summary Allinky Biopharma SL (Allinky) is a developer of small molecules for the treatment of cancer and inflammatory diseases. The company offers research and development of basic and clinical sciences and discovery of novel therapies. Its therapeutic agents comprise active site drugs, target prote …
  • Purepoint Uranium Group Inc (PTU)
    Purepoint Uranium Group Inc (PTU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Electricidade de Mocambique EP:企業の戦略的SWOT分析
    Electricidade de Mocambique EP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Aquila Resources Ltd:企業の戦略・SWOT・財務情報
    Aquila Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Aquila Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Carbonite Inc (CARB):企業の財務・戦略的SWOT分析
    Summary Carbonite Inc (Carbonite) is a subsidiary of Open Text Corporation, is a software development company that provides cloud and hybrid backup products and solutions. The company provides automatic backup solutions for home including personal basic, personal prime, and personal plus, among othe …
  • Chronos Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Chronos Therapeutics Ltd (Chronos) is a research company that offers drug discovery and development services. The company offers research and development, drug discovery, lead optimization, preclinical efficacy, IND enabling, screening, pipeline development and clinical trial services. Its p …
  • ConocoPhillips (COP):企業の財務・戦略的SWOT分析
    ConocoPhillips (COP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • OneWorld Health-製薬・医療分野:企業M&A・提携分析
    Summary OneWorld Health (iOWH) is a healthcare service provider that discovers, develops, and delivers safe, effective, and affordable new treatments for diseases disproportionately affecting people in the world. The center treats infectious diseases such as diarrheal diseases, visceral leishmaniasi …
  • Oragenics Inc (OGEN)-製薬・医療分野:企業M&A・提携分析
    Summary Oragenics Inc (Oragenics) is a biopharmaceutical company that focuses on the development and commercialization of novel antibiotics against infectious disease and develops treatments for oral mucositis. The company develops a new class of potent gram-positive antibiotics which are called Lan …
  • MOL Hungarian Oil and Gas PLC (MOL):石油・ガス:M&Aディール及び事業提携情報
    Summary MOL Hungarian Oil and Gas PLC (MOL) is an integrated oil and gas company. It explores for, develops and produces crude oil, natural gas and other gas products. The company refines, transports and stores crude oil; markets crude oil products on wholesale and retail basis, and produces and sel …
  • Plenus Company Limited:企業の戦略・SWOT・財務分析
    Plenus Company Limited - Strategy, SWOT and Corporate Finance Report Summary Plenus Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Auspex Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Auspex Pharmaceuticals Inc (Auspex), a subsidiary of Teva Pharmaceutical Industries Ltd is a biopharmaceutical company that develops and commercializes novel medicines for the treatment of movement disorders and other rare diseases including orphan diseases. The company offers products for t …
  • Implants International Ltd:企業の製品パイプライン分析
    Summary Implants International Ltd (Implants International) is a medical device company that manufactures, designs, and develops orthopedic implants, bio-engineering, and other products for the healthcare sector. The company’s products include revision systems, hip stems, hip stem ancillaries, aceta …
  • Sino Gas & Energy Holdings Ltd (SEH):石油・ガス:M&Aディール及び事業提携情報
    Summary Sino Gas & Energy Holdings Ltd (Sino Gas), a subsidiary of MIE Holdings Corp, is an oil and gas company that explores and develops unconventional gas assets production sharing contracts. The company holds working interest in the Linxing PSC and the Sanjiaobei PSC projects. It has strategic A …
  • Vectura Group Plc (VEC):製薬・医療:M&Aディール及び事業提携情報
    Summary Vectura Group Plc (Vectura) is a formulation and device business for inhaled airways products providing an integrated inhaled drug delivery platform. It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD) …
  • Ivenix Inc:医療機器:M&Aディール及び事業提携情報
    Summary Ivenix Inc (Ivenix), formerly Fluidnet Corp is a medical technology company that offers infusion therapy solutions. The company offers products such as IV smart pumps and intravenous drug infusion pump systems. Its IV smart pumps eliminate air from fluid bag and IV lines to reduce number of …
  • Euronet Worldwide, Inc.:企業の戦略・SWOT・財務情報
    Euronet Worldwide, Inc. - Strategy, SWOT and Corporate Finance Report Summary Euronet Worldwide, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Charles River Laboratories International Inc (CRL)-医療機器分野:企業M&A・提携分析
    Summary Charles River Laboratories International Inc (Charles River) is a contract research organization (CRO) that provides essential products and services to accelerate the research, drug discovery and development. It offers various basic research, drug discovery and safety assessment services. Th …
  • Cynosure Inc (CYNO)-医療機器分野:企業M&A・提携分析
    Summary Cynosure Inc (Cynosure) develops, manufactures and markets aesthetic and medical treatment systems. The company’s light-based aesthetic treatment systems are used in the treatment of skin revitalization and scar reduction, hair removal, gynecology, pigmentation, tattoo removal, wrinkle reduc …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆